Active — Not RecruitingNot Applicable

New Generation Rehabilitation Approach in Children With Dysfunctional Voiding

Turkey (Türkiye)38 participantsStarted 2025-02-01

Plain-language summary

The investigators hypothesize that Dynamic Neuromuscular Stabilization training, a next-generation exercise approach, and transabdominal ultrasound-guided pelvic floor muscle training (PFMT) will be more effective than PFMT guided solely by transabdominal ultrasound in reducing post-void residual volume, improving voiding disorder symptoms, and enhancing pelvic floor muscle relaxation in children with dysfunctional voiding.

Who can participate

Age range

6 Years – 14 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children aged 6-14 years, * Diagnosed with dysfunctional urination according to uroflowmetry measurement results and clinical examination findings, * Children who consent to participate in the study with the consent of their mother, father or legal guardian (legal representative) will be included in the study. Exclusion criteria: * Children under 6 years of age, * Those with anatomical changes in the urinary system, * Those with spina bifida, * Those with a history of active urinary tract infection, * Those with a neurological disease, * Those with accompanying respiratory system disease, * Those with cognitive impairment, * Those with mental retardation, * Children whose bladder image is unclear in the pelvic floor evaluation with US, * Children who have previously undergone orthopedic surgery will not be included in the study. PS: * Children who cannot comply with the application of pelvic floor muscle training, * Children who have missed 2 or more sessions of the treatment program will be excluded from the study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in the amount of post-void residue

Timeframe: From enrollment to the end of treatment at 8 weeks

Change in EMG-Uroflowmetry measurements-peak flow rate

Timeframe: From enrollment to the end of treatment at 8 weeks

Change in EMG-Uroflowmetry measurements-Pelvic Floor EMG activity

Timeframe: From enrollment to the end of treatment at 8 weeks

Trial details

NCT IDNCT06743165

SponsorIzmir University of Economics

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-01

View on ClinicalTrials.gov More Dysfunctional Voiding trials

Plain-language summary

Who can participate

Age range

6 Years – 14 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in the amount of post-void residue

Timeframe: From enrollment to the end of treatment at 8 weeks

Change in EMG-Uroflowmetry measurements-peak flow rate

Timeframe: From enrollment to the end of treatment at 8 weeks

Change in EMG-Uroflowmetry measurements-Pelvic Floor EMG activity

Timeframe: From enrollment to the end of treatment at 8 weeks